Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
20 studies found for:    Schilder's Disease
Show Display Options
RSS Create an RSS feed from your search for:
Schilder's Disease
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Alpers Huttenlocher Natural History Study
Condition: Alpers Huttenlocher Syndrome
Intervention:
2 Unknown  Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Conditions: Acute Disseminated Encephalomyelitis;   Devic's Syndrome;   Marburg's Variant of Multiple Sclerosis;   Balo's Concentric Sclerosis;   Acute Transverse Myelitis
Intervention: Procedure: Plasma exchange
3 Recruiting Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Endometrioid Tumor;   Malignant Ovarian Serous Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Topotecan Hydrochloride;   Drug: Acetylcysteine
4 Completed
Has Results
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
5 Completed
Has Results
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Drug: irofulven
6 Completed Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
7 Completed Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Conditions: Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
8 Completed
Has Results
Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media
Condition: Chronic Otitis Media
Interventions: Drug: Sulfamethoxazole-trimethoprim;   Drug: Placebo
9 Terminated A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Neoplasms
Intervention: Drug: Volociximab
10 Completed Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: recombinant human stem cell factor;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: mitoxantrone hydrochloride;   Drug: paclitaxel;   Procedure: peripheral blood stem cell transplantation
11 Unknown  Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Elesclomol Sodium;   Drug: Paclitaxel
12 Terminated Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Carcinoma;   Stage III Ovarian Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Paclitaxel;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Topotecan Hydrochloride
13 Completed Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: isotretinoin
14 Completed Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Drug: gefitinib
15 Completed AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Drug: motesanib diphosphate
16 Completed Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: topotecan hydrochloride;   Procedure: peripheral blood stem cell transplantation
17 Terminated Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Condition: Cervical Cancer
Intervention: Drug: gemcitabine hydrochloride
18 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
19 Completed Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: irofulven
20 Recruiting PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Ovarian Cancer
Interventions: Drug: IMGN853;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Topotecan

Study has passed its completion date and status has not been verified in more than two years.